GH1 and intracranial hemorrhage: More recently, data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) study raised concerns for premature mortality (10) and intracranial hemorrhage (11) in young adults treated with GH during childhood.